Professional profile
About Ouxiang
Medical Devices and IVD Compliance in Shanghai Pudong
Ouxiang Hao advises manufacturers, importers and distributors on medical device and in-vitro diagnostic (IVD) regulatory compliance, product registration pathways and commercial contracting for China market access from Shanghai’s Pudong life-sciences corridor.
Mr. Hao practices at Shanghai AllBright Law Offices. He was admitted in 2012 and has about fourteen years of professional experience, working in English and Mandarin with Shanghai Bar Association credentials on file.
Device and IVD files are multi-regulator and multi-contract. Registration classifications, clinical evaluation expectations, labelling, advertising claims and distributor quality agreements must align. Global HQ templates that ignore China-specific pathways create launch delays and inspection risk.
Registration, Quality Agreements and Promotional Claims
He maps product classification and evidence needs with regulatory consultants where technical dossiers require specialist input, keeping legal ownership of risk allocation clear. Quality agreements with contract manufacturers and logistics partners need audit rights and change-control clauses that match actual operations.
Advertising and KOL promotion of devices is a recurring enforcement theme. Claim language that works in English marketing often oversteps Chinese standards. He pre-clears customer-facing materials and training decks.
Adverse event and recall communications are sequenced with insurer and distributor notice duties so messages stay consistent.
Disputes and Cross-Border Supply
When products are detained, delisted or disputed under supply contracts, he builds enforcement and settlement strategies with bilingual summaries for overseas manufacturers. Parallel IP and unfair-competition issues are coordinated rather than siloed.
How to Engage
Provide product type, current registration status, target launch timing and any inspection or complaint notice already received. Scope is confirmed in writing through this profile’s inquiry channel.
Clinical Evaluation, Labeling and Post-Market Duties
Device classification drives evidence expectations. Mr. Hao works with regulatory specialists on dossier strategy while keeping legal ownership of risk allocation in contracts and board updates. Labeling and IFU language must match cleared indications; marketing drift is a common inspection finding.
Post-market surveillance, complaint handling and adverse event reporting need SOPs that field teams follow. He reviews whether distributors actually escalate complaints or quietly discount them—a gap that becomes catastrophic in a serious incident.
UDI, traceability and warehouse practices affect recall readiness. Paper SOPs without system support are treated as residual risk that leadership should accept explicitly or fix.
Cross-border clinical data and privacy constraints interact with device files. He coordinates with privacy counsel when patient-level data moves for vigilance or studies.
Tenders, Hospitals and Commercial Disputes
Hospital and group purchasing negotiations create contract and anti-bribery touchpoints. Training and third-party intermediary management are part of legal risk, not only commercial ops.
When tenders are lost over compliance allegations or products are suspended, he builds response strategies with bilingual briefs for overseas manufacturers facing China-only facts.
Clients receive a written staged plan that separates urgent deadlines from longer evidence workstreams, so commercial teams do not improvise communications that later become exhibits.
Where overseas stakeholders must approve settlements or major filings, bilingual summaries state confirmed facts, open questions and the decision required by a stated date.
Document holds on email and messaging should begin when a dispute or inquiry is reasonably anticipated; quiet deletions by well-meaning staff create narratives that are hard to unwind.
Authority to settle, pay or make public statements is confirmed at intake. Ambiguous authority creates delay and evidence risk when informal promises are later denied.
Remote consultations are available for parties outside the primary city. Chinese-language work product remains available where authorities or counterparties require it.
Preparation Notes for Cross-Border Clients
Cross-border matters fail when sales, finance and legal each hold a different version of the facts. A single chronology with source notes becomes the spine of strategy. Assumptions should be labelled so headquarters can decide under uncertainty without inventing certainty.
Document holds on email and messaging should begin when a dispute or regulatory inquiry is reasonably anticipated. Quiet deletions by well-meaning staff create narratives that are difficult to unwind. Counsel should issue hold instructions in language operations teams understand.
Authority to settle, pay, or make public statements must be clear at intake. Ambiguous authority creates both delay and evidence risk when informal promises are later denied. Engagement letters state who the client is and who may give instructions.
Response windows on notices, hearings and administrative inquiries are part of legal risk analysis, not administrative noise. Calendars should include translation and corporate approval buffers so deadlines are not missed for logistical reasons.
Settlement paper needs enforceability: payment security, default consequences, and cooperation duties for registrations or platform actions where relevant. Handshake discounts without teeth often return as second disputes.
Remote consultations are available for parties outside the primary city. Chinese-language work product remains available where authorities or counterparties require it. Inquiries through this profile should include a short chronology, the top documents available within forty-eight hours, and every fixed deadline already running.
Additional Planning Notes (Stage 2)
Capability
